Arcentales-Vera Karla, Vera-Mendoza María Fernanda, Cevallos-Salas Cristian, García-Aguilera María Fernanda, Fuenmayor-González Luis
Postgrado en Medicina Crítica y Terapia Intensiva, Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador.
Unidad de Terapia Intensiva, Hospital de Especialidades Carlos Andrade Marín, Quito, Ecuador.
Sci Prog. 2024 Oct-Dec;107(4):368504241308982. doi: 10.1177/00368504241308982.
Intradialytic hypotension (IDH) is a common and serious complication in renal replacement therapy, especially in hospitalized patients. The absence of a standardized definition complicates data synthesis and the development of evidence-based guidelines. Current definitions vary, including different blood pressure thresholds, clinical symptoms, and the need for medical intervention during dialysis. IDH is linked to increased mortality and cardiovascular morbidity and may impede renal recovery in patients with acute kidney injury and chronic kidney disease.
A systematic review was conducted using MEDLINE via PubMed, Embase, and Web of Science to identify studies reporting IDH prevalence. A meta-analysis of proportions was performed to determine the global prevalence of IDH, with subgroup analyses to explore heterogeneity. The Joanna Briggs Institute's checklist was used to assess the risk of bias in prevalence studies. The PRISMA guidelines were followed to report the results of this study, PROSPERO registration number CRD42024500622.
The meta-analysis found a global IDH prevalence of 31% (95% CI 0.18-0.44) across nine studies. Significant heterogeneity was observed (I²: 97.87%; < 0.01), with prevalence rates ranging from 10.7% to 64% based on patient demographics and session characteristics. Sensitivity analysis suggested prevalence could range between 27% and 33% depending on study criteria.
IDH is a significant complication during hospital-based renal replacement therapy, with a global prevalence of 31%. These findings highlight the need for a standardized, evidence-based definition of IDH to improve diagnostic consistency and clinical outcomes through more accurate diagnosis, better treatment strategies, and tailored patient management.
透析中低血压(IDH)是肾脏替代治疗中常见且严重的并发症,在住院患者中尤为如此。缺乏标准化定义使数据综合分析以及循证指南的制定变得复杂。目前的定义各不相同,包括不同的血压阈值、临床症状以及透析期间是否需要医疗干预。IDH与死亡率增加和心血管疾病发病率上升相关,可能会阻碍急性肾损伤和慢性肾病患者的肾脏恢复。
通过PubMed、Embase和Web of Science对MEDLINE进行系统综述,以识别报告IDH患病率的研究。进行比例的荟萃分析以确定IDH的全球患病率,并进行亚组分析以探索异质性。使用乔安娜·布里格斯研究所的清单评估患病率研究中的偏倚风险。本研究结果的报告遵循PRISMA指南,PROSPERO注册号为CRD42024500622。
荟萃分析发现,九项研究的全球IDH患病率为31%(95%CI 0.18 - 0.44)。观察到显著的异质性(I²:97.87%;P < 0.01),根据患者人口统计学和透析时段特征,患病率从10.7%到64%不等。敏感性分析表明,根据研究标准,患病率可能在27%至33%之间。
IDH是住院肾脏替代治疗期间的一种重要并发症,全球患病率为31%。这些发现凸显了对IDH进行标准化、循证定义的必要性,以便通过更准确的诊断、更好的治疗策略和个性化的患者管理来提高诊断一致性和临床结局。